Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction

Katja Ott(Technical University of Munich), Jörg‐Rüdiger Siewert(University of California, Los Angeles), Hinrich Wieder(Klinikum rechts der Isar), Florian Lordick(Leipzig University), Wolfgang Weber(Nuklearmedizinische Klinik des Klinikums rechts der Isar), U. Fink(Technical University of Munich), Karen Becker(Technical University of Munich), Markus Schwaiger(Technical University of Munich), Raymonde Busch(University of California, Los Angeles), Ken Herrmann(Essen University Hospital)
Journal of Clinical Oncology
September 12, 2006
10.1200/jco.2006.06.7801
Cited by 464

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|1.1k